SABRA MAZIN 4
4 · ClearPoint Neuro, Inc. · Filed Feb 19, 2026
Research Summary
AI-generated summary of this filing
ClearPoint Neuro (CLPT) COO Sabra Mazin Receives RSU Award
What Happened
- Sabra Mazin, Chief Operating Officer of ClearPoint Neuro (CLPT), was granted 36,818 restricted stock units (RSUs) on February 17, 2026. The award is reported as a derivative grant at $0.00 per unit (no immediate cash value).
Key Details
- Transaction date: February 17, 2026; Form 4 filed February 19, 2026 (accession 0001193125-26-059398).
- Grant: 36,818 restricted stock units (RSUs), acquisition code A; reported price $0.00.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Footnotes: F1 — each RSU represents a contingent right to one share of CLPT common stock. F2 — vesting: 20% on Feb 17, 2027; 40% on Feb 17, 2028; 40% on Feb 17, 2029.
- Timeliness: Filing dated Feb 19, 2026; within the typical two-business-day Form 4 reporting window.
Context
- These RSUs are compensation awards that convert into common stock only if and when they vest per the schedule above; they are not an open-market purchase or sale. Such grants are a non-cash form of pay/retention and do not by themselves indicate insider buying or selling intent.
Insider Transaction Report
Form 4
SABRA MAZIN
Chief Operating Officer
Transactions
- Award
Restricted Stock Units
[F1][F2]2026-02-17+36,818→ 36,818 total→ Common Stock (36,818 underlying)
Footnotes (2)
- [F1]Each restricted stock unit represents a contingent right to receive one share of CLPT common stock.
- [F2]The restricted stock units vest as follows: (i) 20% of the total shares on February 17, 2027; (ii) 40% of the total shares on February 17, 2028; and (iii) 40% of the total shares on February 17, 2029.
Signature
/s/ Danilo D'Alessandro, by Power of Attorney for Mazin Sabra|2026-02-19